Strides Pharma Science has notified the stock exchanges of an upcoming Board of Directors meeting scheduled for Monday, May 18, 2026, pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In addition, the company has also scheduled an Earnings Call for investors and analysts on the same date to discuss its audited financial results for the quarter and financial year ended March 31, 2026. Both intimations were filed on May 11, 2026, and signed by Manjula Ramamurthy, Company Secretary & Compliance Officer.

Key Agenda Items

The board meeting has been convened to address two primary matters, as outlined in the regulatory filing:

Earnings Call Details

The company has scheduled a conference call for investors and analysts to interact with senior management on Q4FY26 performance. The details of the earnings call are as follows:

Participants from the management include Badree Komandur, Managing Director & Group CEO, and Vikesh Kumar, Group CFO.

Dial-In Numbers

Investors and analysts may join the earnings call through the following dial-in numbers:

For any queries, investors may reach out to investor-relations@strides.com .

Trading Window Closure

In accordance with the Company's Code of Conduct for Prohibition of Insider Trading, the trading window for Designated Persons of the Company has been closed effective April 1, 2026. The trading window will reopen 48 hours after the declaration of financial results by the Company.

The company has stated that the above information will also be made available on its official website at www.strides.com . The filing was submitted to both the National Stock Exchange of India Limited and BSE Limited for information and record purposes.

Strides Pharma Science Limited has completed its regulatory compliance obligations by submitting the mandatory certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The pharmaceutical company filed the necessary documentation through its registrar and share transfer agent, KFin Technologies Limited.

Regulatory Compliance Framework

The certificate submission forms part of the company's ongoing compliance with securities market regulations. Under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, companies are required to provide periodic certifications regarding the dematerialization and rematerialization of securities during specified quarters.

Certificate Submission Details

KFin Technologies Limited, acting as the registrar to the issue and share transfer agent for Strides Pharma Science Limited, certified that all required details of securities transactions have been properly reported. The certification covers the period ending March 31, 2026, and confirms compliance with regulatory requirements.

Depository Communications

The certificates were formally submitted to both major depositories in India. KFin Technologies Limited addressed separate communications to National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL), confirming that details of securities dematerialized and rematerialized during the quarter have been furnished to all stock exchanges where the company's shares are listed.

Stock Exchange Notifications

Strides Pharma Science Limited's Company Secretary and Compliance Officer, Manjula Ramamurthy, formally notified both the National Stock Exchange of India Limited and The BSE Limited about the certificate submission. The company trades on NSE under the scrip code STAR and on BSE under scrip code 532531.

Corporate Information

The company maintains its corporate office at Strides House, Bilekahalli, Bannerghatta Road, Bengaluru, while its registered office is located at Cyber One, Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai. KFin Technologies Limited operates from its registered office in Mumbai and maintains operational facilities in Hyderabad.